Published On: 3/18/2020
COVID-19 Response
Based on the current recommendations from the CDC and Governor of North Carolina, the entire TARGET PharmaSolutions staff has transitioned to a remote working environment. During this time, TARGET expects work to continue as usual.
TARGET shares its support to all of those who have been affected by the expanding global corona virus, or COVID-19, outbreak.
Stay up-to-date on the virus from the World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel-coronavirus-2019
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life -
03/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry) -
03/07/2025
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies -
02/20/2025
Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data -
01/31/2025
Maximizing the Value of Real-World Data: The Critical Role of Causal Inference in Pharmaceutical Innovation